Peptide synthesis is the formation of a bond between two amino acids and usually refers to chains of up to 30-50 amino acids. When a chain gets especially long it turns into a protein. Peptides and proteins are used extensively by molecular biologists for research and product and drug development.
Protein Technologies designs, manufactures and supplies peptide synthesizers and reagents to academic and commercial researchers at universities, biotechnology and pharmaceutical companies. The company was founded in 1985 by researchers affiliated with the University of Arizona and is headquartered in Tucson, AZ (www.ptipep.com).
Under Ampersand’s ownership, Nate Cosper, Ph.D., will continue to serve as President and CEO of the company. “Ampersand’s acquisition strengthens our balance sheet, enabling our company to accelerate development of new products and enhance the level of service that we provide to our customers,” said Dr. Cosper.
The acquisition of the company by Ampersand provides the company with the capital base needed to expand the business and meet the needs of an increasingly global customer base. “Protein Technologies is the recognized leader in a segment of the life sciences instrument market that is experiencing strong demand based on worldwide research interest in novel, peptide-based therapies,” said David Parker, General Partner at Ampersand.
Ampersand makes equity investments of $10 million to $30 million in healthcare related companies that have from $10 million to $100 million of revenue. Ampersand is typically the first institutional investor in founder-owned businesses. Sectors of specific interest within healthcare include laboratory services; laboratory products; contract manufacturing; pharmaceutical services; and specialty pharmaceuticals. Ampersand is based in the Boston suburb of Wellesley, MA (www.ampersandcapital.com).
Square 1 Bank (www.square1financial.com) is providing working capital financing to Protein Technologies in tandem with the acquisition of the company by Ampersand.
© 2015 PEPD • Private Equity’s Leading News Magazine • 6-18-15